ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
ZEISS (OTC:CZMWY) has received CE mark approval for its CIRRUS PathFinder, an AI-powered clinical support tool for OCT interpretation. The technology integrates proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans, enhancing diagnostic workflows and patient care efficiency.
The new software release includes AI-enhanced OCTA image quality, multi-layer segmentation, and expanded reference database that is triple the size of the previous version. The system can assess hundreds of scans simultaneously in real-time, flagging areas requiring detailed imaging without third-party platforms.
The tool is available in select markets as a licensed element within the new CIRRUS software update, which also features enhanced cybersecurity measures and seamless integration with legacy OCT data.
ZEISS (OTC:CZMWY) ha ottenuto il marchio CE per CIRRUS PathFinder, uno strumento clinico basato sull'IA per l'interpretazione degli OCT. La tecnologia utilizza algoritmi proprietari di deep learning per identificare automaticamente B-scan maculari anomali, migliorando i flussi diagnostici e l'efficienza dell'assistenza ai pazienti.
La nuova versione del software include miglioramento IA della qualit脿 delle immagini OCTA, segmentazione multistrato e un database di riferimento ampliato, triplo rispetto alla versione precedente. Il sistema 猫 in grado di analizzare centinaia di scansioni contemporaneamente in tempo reale, segnalando le aree che richiedono imaging dettagliato senza ricorrere a piattaforme di terze parti.
Lo strumento 猫 disponibile in mercati selezionati come componente con licenza nell'aggiornamento software CIRRUS, che integra anche misure di cybersecurity potenziate e integrazione fluida con i dati OCT legacy.
ZEISS (OTC:CZMWY) ha recibido la aprobaci贸n del marcado CE para CIRRUS PathFinder, una herramienta cl铆nica impulsada por IA para la interpretaci贸n de OCT. La tecnolog铆a integra algoritmos propietarios de deep learning para identificar autom谩ticamente B-scans maculares an贸malos, mejorando los flujos diagn贸sticos y la eficiencia en la atenci贸n al paciente.
La nueva versi贸n del software incluye calidad de imagen OCTA mejorada con IA, segmentaci贸n multicapa y una base de referencia ampliada que es tres veces mayor que la anterior. El sistema puede evaluar cientos de exploraciones simult谩neamente en tiempo real, se帽alando 谩reas que requieren im谩genes detalladas sin necesidad de plataformas de terceros.
La herramienta est谩 disponible en mercados selectos como elemento con licencia dentro de la actualizaci贸n de software CIRRUS, que tambi茅n incorpora medidas de ciberseguridad reforzadas e integraci贸n sin fisuras con datos OCT heredados.
ZEISS (OTC:CZMWY)臧� AI 旮半皹 鞛勳儊 歆�鞗� 霃勱惮鞚� CIRRUS PathFinder鞐� 雽�頃� CE 毵堩伂 鞀轨澑鞚� 氚涭晿鞀惦媹雼�. 鞚� 旮办垹鞚� 霃呾瀽鞝侅澑 霐ル煬雼� 鞎岅碃毽鞚� 韱淀暕頃橃棳 鞚挫儊 頇╇皹 OCT B-鞀れ簲鞚� 鞛愲彊鞙茧 鞁濍硠頃� 歆勲嫧 鞗岉伂頂岆鞕� 頇橃瀽 甏�毽� 須湪鞚� 頄レ儊鞁滍偟雼堧嫟.
靸� 靻岉攧韸胳洦鞏� 氩勳爠鞐愲姅 AI 頄レ儊 OCTA 頇旍, 雼れ傅 攵勴暊, 鞚挫爠 氩勳爠氤措嫟 3氚� 旎れ 頇曥灔霅� 彀胳“ 雿办澊韯半矤鞚挫姢臧� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞁滌姢韰滌潃 鞁れ嫓臧勳溂搿� 靾橂氨 瓯挫潣 鞀れ簲鞚� 霃欖嫓鞐� 韽夑皜頃� 於旉皜 鞝曤皜 齑榿鞚� 頃勳殧頃� 鞓侅棴鞚� 鞝�3鞛� 頂岆灚韽� 鞐嗢澊霃� 響滌嫓頃� 靾� 鞛堨姷雼堧嫟.
頃措嫻 霃勱惮電� 靹犿儩霅� 鞁滌灔鞐愳劀 靸� CIRRUS 靻岉攧韸胳洦鞏� 鞐呺嵃鞚错姼鞚� 霛检澊靹犾姢 鞖旍唽搿� 鞝滉车霅橂┌, 臧曧檾霅� 靷澊氩� 氤挫晥 臁办箻鞕� 旮办〈 OCT 雿办澊韯办檧鞚� 鞗愴櫆頃� 韱淀暕 旮半姤霃� 韽暔頃╇媹雼�.
ZEISS (OTC:CZMWY) a obtenu le marquage CE pour CIRRUS PathFinder, un outil d'aide clinique aliment茅 par l'IA pour l'interpr茅tation des OCT. La technologie int猫gre des algorithmes de deep learning propri茅taires pour identifier automatiquement les B-scans maculaires anormaux, am茅liorant les processus diagnostiques et l'efficacit茅 des soins aux patients.
La nouvelle version du logiciel comprend am茅lioration IA de la qualit茅 des images OCTA, segmentation multi-couches et une base de r茅f茅rence 茅largie trois fois plus importante que la pr茅c茅dente. Le syst猫me peut analyser des centaines de scans simultan茅ment en temps r茅el, signalant les zones n茅cessitant une imagerie d茅taill茅e sans recourir 脿 des plateformes tierces.
L'outil est disponible sur certains march茅s en tant qu'茅l茅ment licenci茅 dans la mise 脿 jour logicielle CIRRUS, qui int猫gre 茅galement des mesures de cybers茅curit茅 renforc茅es et une int茅gration transparente avec les donn茅es OCT existantes.
ZEISS (OTC:CZMWY) hat die CE-Kennzeichnung f眉r CIRRUS PathFinder erhalten, ein KI-gest眉tztes klinisches Unterst眉tzungstool zur OCT-Interpretation. Die Technologie nutzt propriet盲re Deep-Learning-Algorithmen, um abnormalen makul盲ren OCT-B-Scans automatisch zu erkennen und damit diagnostische Abl盲ufe und die Effizienz der Patientenversorgung zu verbessern.
Das neue Software-Release umfasst KI-verbesserte OCTA-Bildqualit盲t, Mehrschichtsegmentierung und eine erweiterte Referenzdatenbank, die dreimal so gro脽 ist wie zuvor. Das System kann Hunderte von Scans gleichzeitig in Echtzeit auswerten und Bereiche markieren, die einer detaillierteren Bildgebung bed眉rfen, ohne Drittanbieterplattformen.
Das Tool ist in ausgew盲hlten M盲rkten als lizenziertes Element im neuen CIRRUS-Softwareupdate verf眉gbar, das zudem verbesserte Cybersicherheitsma脽nahmen und nahtlose Integration mit bestehenden OCT-Daten bietet.
- Received CE mark approval for AI-powered diagnostic tool
- Technology can process hundreds of scans simultaneously in real-time
- Reference Database expanded to triple its previous size
- Fully integrated solution eliminates need for third-party platforms
- Enhanced cybersecurity features for improved compliance
- Limited availability to select markets only
- Requires additional license purchase for access
- Full Reference Database functionality limited to CIRRUS 6000 devices
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.
JENA,
"At ZEISS, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience."
"ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care," says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into ZEISS CIRRUS PathFinder."
New shows that physicians who leverage AI algorithms can be more effective than a practitioner alone. ZEISS CIRRUS with PathFinder delivers high-speed image capture with HD imaging detail 2, a wide field of view, and AI decision support, helping clinicians make more informed and efficient decisions.
"With PathFinder AI Decision Support, our game-changing technology identifies OCT B-scans that may require additional review, raising our advanced diagnostic portfolio to a new level of patient care support," says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. 听听
Improved clinical decision support 鈥� Without requiring export and data analysis from third-party platforms, CIRRUS PathFinder's fully integrated AI decision support algorithm interprets data within the clinician's current workflow, allowing for the assessment of many hundreds of scans at once, in real time, upleveling the value of a clinician's time. During image acquisition, this AI-guided workflow tool flags areas that may require more detailed imaging and, during review, allows the user to focus on what matters 鈥� improving patient care.
Improved OCTA image quality 鈥� New CIRRUS operating software provides AI-enhanced visualization of the vascular structure and B-scan averaging of the OCTA structural scans. Increased layer segmentation further enhances the user's diagnostic capability for even more efficient decision making.
Enhanced connectivity and security 鈥� New cybersecurity features are designed to meet ever-evolving compliance and security needs. Additionally, the ZEISS CIRRUS platform ensures the seamless review of legacy OCT data combined with other diagnostic modalities to further enhance patient care.
CIRRUS庐 笔补迟丑贵颈苍诲别谤鈩� is available via license within the new CIRRUS software update, which includes an expanded Reference Database (RDB) that is triple the size of the previous RDB, cybersecurity enhancements, multi-layer segmentation, and improved OCTA visualization. The software update is available in select markets.
For more information about CIRRUS PathFinder, go .
1 ZEISS PathFinder works on all current ZEISS CIRRUS devices: 500, 5000, 6000, however RDB2 is for ZEISS CIRRUS 6000 data only.
2 As it relates to the ZEISS CIRRUS 6000 only.
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content.听The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.听
Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: [email protected]
Contact for the press
Frank Smith
Head of Global Communications
ZEISS Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: [email protected]
听 听 听 听 听听
Brief Profile
Carl听Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of
The Group's head office is located in Jena,
For further information visit:听
听
View original content to download multimedia:
SOURCE Carl Zeiss Meditec AG
FAQ
What is the ZEISS CIRRUS PathFinder and what did it receive CE mark approval for?
How does the ZEISS CIRRUS PathFinder AI tool improve clinical workflow?
What new features are included in the ZEISS CIRRUS software update?
Which ZEISS CIRRUS devices are compatible with PathFinder?
How does ZEISS CIRRUS PathFinder support clinical decision-making?
